Femasys (FEMY) Return on Capital Employed (2021 - 2025)
Femasys' (FEMY) quarterly Return on Capital Employed came in at 746.57% in Q2 2025, down 66361.0% YoY from N/an in Q2 2024, and down 13.97% on a QoQ basis from 655.03% in Q1 2025.
Femasys (FEMY) Return on Capital Employed (2021 - 2025) Analysis & Trends
Femasys (FEMY) has 5 years of Return on Capital Employed data on file, last reported at 746.57% in Q2 2025.
- Quarterly Return on Capital Employed fell 66361.0% year-over-year to 746.57% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 746.57% (down 66361.0% YoY) and the FY2025 annual result came in at 135.84%, up 1859.0% from the prior year.
- Return on Capital Employed slipped to 746.57% in Q2 2025, from 655.03% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 24.85% in Q3 2021 to a low of 746.57% in Q2 2025.
- A 5-year average of 163.46% and a median of 81.23% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 2120 bps — and 2025, when it plunged 66361 bps.
- Tracing FEMY's Return on Capital Employed over 5 years: stood at 29.59% in 2021, then slumped by 132 bps to 68.49% in 2022, then dropped by 16 bps to 79.5% in 2023, then tumbled by 312 bps to 327.42% in 2024, then slumped by 128 bps to 746.57% in 2025.
- The last three Return on Capital Employed figures came in at 746.57% (Q2 2025), 655.03% (Q1 2025), and 327.42% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 18.58% |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 6.00% |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | 28.11% |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 25.22% |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | 5.57% |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 19.71% |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 19.76% |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | 4.68% |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 3.28% |
| 10 | Femasys | 8.98 Mn | 7.54 Mn | 189,391.00 | -181.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -746.57% |
| Mar 31, 2025 | -655.03% |
| Dec 31, 2024 | -327.42% |
| Sep 30, 2024 | -116.26% |
| Jun 30, 2024 | -82.96% |
| Mar 31, 2024 | -62.98% |
| Dec 31, 2023 | -79.50% |
| Sep 30, 2023 | -105.34% |
| Jun 30, 2023 | -94.69% |
| Mar 31, 2023 | -84.18% |
| Dec 31, 2022 | -68.49% |
| Sep 30, 2022 | -55.43% |
| Jun 30, 2022 | -45.20% |
| Mar 31, 2022 | -36.95% |
| Dec 31, 2021 | -29.59% |
| Sep 30, 2021 | -24.85% |